Much debate was ignited by a marginally significant 16% ( P = 0.052) reduction in fatal and nonfatal myocardial infarction in the UKPDS where chlorpropamide, glibenclamide, or glipizide were used as initial therapy in newly diagnosed uncomplicated diabetic patients ( 1 ).
A significant reduction in the predefined secondary composite end point of all-cause mortality, nonfatal myocardial infarction, and stroke (HR 0.84, 95% CI 0.72–0.98; P = 0.027) was found, although primary composite end point (all-cause mortality, nonfatal myocardial infarction, stroke, major leg amputation, acute coronary syndrome, cardiac or leg revascularization) did not reach statistical significance ( 31 ).